Pill imprint O-M 50 has been identified as Nucynta tapentadol 50 mg. Nucynta is used in the treatment of pain and belongs to the drug classes Analgesics, narcotic analgesics. Risk cannot be ruled out during pregnancy.
Tapentadol (trade names: Nucynta, Palexia, in India available as TAPAL by MSN Labs) is a centrally acting analgesic with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor. It is also an agonist of the receptor2σ, though the function of this orphan receptor remains controversial. pain
A combination drug most commonly refers to a fixed-dose combination (FDC), which is a formulation including two or more active pharmaceutical ingredients (APIs) combined in a single dosage form, which is manufactured and distributed in certain respective fixed doses. Terms like "combination drug" or "combination drug product" can be common shorthand for a FDC product (since most combination drug products are currently FDCs), although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages (as opposed to customized polypharmacy via compounding). And it should also be distinguished from the term "combination product" in medical contexts, which without further specification can refer to products that combine different types of medical products - such as device/drug combinations as opposed to drug/drug combinations. Note that when a combination drug product (whether fixed-dose or not) is a "pill" (i.e., a tablet or capsule), then it is also a kind of "polypill" or combopill.
Initially, fixed-dose combination drug products were developed to target a single disease (such as with antiretroviral FDCs used against AIDS). However, FDCs may also target multiple diseases/conditions, such as Caduet (atorvastatin/amlodipine) or Exforge (amlodipine/valsartan). In cases of FDCs targeting multiple conditions, such conditions might often be related — in order to increase the number of prospective patients who might be likely to utilize a given FDC product. This is because each FDC product is mass-produced, and thus typically requires having a critical mass of potentially applicable patients in order to justify its manufacture, distribution, stocking, etc. Opioids
Health Medical Pharma
Health Medical Pharma